Human Genome Epidemiology Literature Finder
|
Records 1 - 16 (of 16 Records) |
| Query Trace: Diarrhea and TP53[original query] |
|---|
| Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics 2010 Oct 11 (10): 1377-87. Sakano Shigeru, Hinoda Yuji, Sasaki Miwa, Wada Takashi, Matsumoto Hiroaki, Eguchi Satoshi, Shinohara Asano, Kawai Yoshihisa, Hara Tomohiko, Nagao Kazuhiro, Hara Takahiko, Naito Katsusuke, Matsuyama Hideya |
| Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 May 26 (5): 1012-8. Fu S, Hou M M, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam |
| A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Nov . Ma Cynthia X, Luo Jingqin, Naughton Michael, Ademuyiwa Foluso O, Suresh Rama, Griffith Malachi, Griffith Obi L, Skidmore Zachary, Spies Nicholas C, Ramu Avinash, Trani Lee, Pluard Timothy, Nagaraj Gayathri, Thomas Shana N, Guo Zhanfang, Hoog Jeremy, Han Jing, Mardis Elaine R, Lockhart A Craig, Ellis Matthew |
| A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. Clinical cancer research : an official journal of the American Association for Cancer Research 2018 Aug . Lheureux Stephanie, Tinker Anna, Clarke Blaise, Ghatage Prafull, Welch Stephen, Weberpals Johanne I, Dhani Neesha C, Butler Marcus O, Tonkin Katia, Tan Qian, Tan David S P, Brooks Kelly, Ramsahai Janelle, Wang Lisa, Pham Nhu-An, Shaw Patricia A, Tsao Ming S, Garg Swati, Stockley Tracey, Oza Amit |
| Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotyping. Medical oncology (Northwood, London, England) 2018 May 35 (7): 101. Papaxoinis George, Kotoula Vassiliki, Giannoulatou Eleni, Koliou Georgia-Angeliki, Karavasilis Vasilios, Lakis Sotirios, Koureas Andreas, Bobos Mattheos, Chalaralambous Elpida, Daskalaki Emily, Chatzopoulos Kyriakos, Tsironis George, Pazarli Elisavet, Chrisafi Sofia, Samantas Epaminontas, Kaklamanos Ioannis G, Varthalitis Ioannis, Konstantara Athina, Syrigos Konstantinos N, Pentheroudakis George, Pectasides Dimitrios, Fountzilas Geor |
| Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299. Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo |
| Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. Cancer research and treatment 2018 Jan . Yoo Changhoon, Han Boram, Kim Hyeong Su, Kim Kyu-Pyo, Kim Deokhoon, Jeong Jae Ho, Lee Jae-Lyun, Kim Tae Won, Kim Jung Han, Choi Dae Ro, Ha Hong Il, Seo Jinwon, Chang Heung-Moon, Ryoo Baek-Yeol, Zang Dae You |
| Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. Investigational new drugs 2020 2 38 (5): 1430-1441. Uy Geoffrey L, Assouline Sarit, Young Anne-Marie, Blotner Steven, Higgins Brian, Chen Lin-Chi, Yee Kar |
| Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific reports 2020 2 10 (1): 3080. Wang Yudong, Janku Filip, Piha-Paul Sarina, Hess Kenneth, Broaddus Russell, Liu Lidong, Shi Naiyi, Overman Michael, Kopetz Scott, Subbiah Vivek, Naing Aung, Hong David, Tsimberidou Apostolia M, Karp Daniel, Yao James, Fu Siqi |
| Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3K? inhibitor therapy. Blood 2020 12 137 (20): 2817-2826. Mato Anthony R, Ghosh Nilanjan, Schuster Stephen J, Lamanna Nicole, Pagel John M, Flinn Ian W, Barrientos Jacqueline C, Rai Kanti R, Reeves James A, Cheson Bruce D, Barr Paul M, Kambhampati Suman, Lansigan Frederick, Pu Jeffrey J, Skarbnik Alan P, Roeker Lindsey, Fonseca Gustavo A, Sitlinger Andrea, Hamadeh Issam S, Dorsey Colleen, LaRatta Nicole, Weissbrot Hanna, Luning Prak Eline T, Tsao Patricia, Paskalis Dana, Sportelli Peter, Miskin Hari P, Weiss Michael S, Svoboda Jakub, Brander Danielle |
| Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. Blood advances 2021 5 5 (9): 2438-2446. Tomowiak Cécile, Poulain Stéphanie, Herbaux Charles, Perrot Aurore, Mahé Béatrice, Morel Pierre, Aurran Thérèse, Tournilhac Olivier, Leprêtre Stéphane, Assaad Souad, Villemagne Bruno, Casasnovas Olivier, Nollet Delphine, Roos-Weil Damien, Chevret Sylvie, Leblond Véroniq |
| Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. Frontiers in molecular biosciences 2021 5 8 639892. Yang Xue, Xia Yang, Xu Liyan, Liang Li, Zhuo Minglei, Wu Meina, An Tongtong, Wang Ziping, Wang Yuyan, Li Jianjie, Zhong Jia, Chen Hanxiao, Jia Bo, Wang Jingjing, Zhao J |
| First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. European journal of cancer (Oxford, England : 1990) 2022 Sep 173 238-249. Ma Yuxiang, Zhao Hongyun, Xue Jinhui, Liu Li, Yang Nong, Zhang Yang, Yang Haiyan, Hong Shaodong, Xiong Yi, Zhang Zhonghan, Zeng Liang, Pan Hui, Zhou Chunhua, Zhang Yongchang, Wang Xunqiang, Han Xi, Wan Xiaojing, Shao Yang, Liu Jingwen, Yang Yunpeng, Huang Yan, Zhao Yuanyuan, Fang Wenfeng, Li Su, Zhang |
| Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L). Lung cancer (Amsterdam, Netherlands) 2022 4 168 38-45. Hayashi Hidetoshi, Yonesaka Kimio, Nakamura Atsushi, Fujimoto Daichi, Azuma Koichi, Sakata Shinya, Tachihara Motoko, Ikeda Satoshi, Yokoyama Toshihide, Hataji Osamu, Yano Yukihiro, Hirano Katsuya, Daga Haruko, Okada Hideaki, Chiba Yasutaka, Sakai Kazuko, Nishio Kazuto, Yamamoto Nobuyuki, Nakagawa Kazuhi |
| Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 9 JCO2202604. Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard A Larson, Adam S Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N Tanaka, Terrence J Bradley, Deepa Jeyakumar, Eunice S Wang, Kendra Sweet, Hagop M Kantarjian, Guillermo Garcia-Manero, Rami Komrokji, Guan Xing, Giridharan Ramsingh, Camille Renard, Joshua F Zeidner, David A Sallm |
| Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042). Clinical cancer research : an official journal of the American Association for Cancer Research 2023 5 . Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, James Moon, Philip C Mack, Gregory J Gerstner, Timothy F Burns, Asma Taj, Wallace L Akerley, Konstantin H Dragnev, Noel Laudi, Mary W Redman, Jhanelle E Gray, David R Gandara, Karen Kel |
- Page last reviewed:Feb 1, 2023
- Page last updated:Sep 29, 2023
- Content source: